Our verdict — 2.8 / 5
Priced competitively, but the reason to buy compounded has mostly gone. ShedRx’s cheapest tirzepatide costs $60 a month less than the FDA-approved drug bought straight from Eli Lilly — in exchange for a preparation the FDA has not reviewed, from a pharmacy ShedRx will not name, on a 12-month contract that reprices retroactively if you stop early. If you want a GLP-1 and you want it approved, buy the brand. If you have already decided on compounded, ShedRx’s all-in price is genuinely the lowest in our comparison.
BalanzGM is reader-supported. Some links on this page are affiliate links — if you sign up through them we may earn a commission at no extra cost to you. It does not change a single figure or conclusion below. See our affiliate disclosure.
This review summarizes what ShedRx publishes about itself, alongside FDA statements, a federal appellate ruling and competitors’ own published prices — each cited at the foot of the page. It is written by journalists, not clinicians, and has not been reviewed by a physician. Whether a GLP-1 medication is appropriate for you is a decision for a US-licensed clinician who has evaluated you. Full medical disclaimer.
What this review found
- ShedRx’s headline product is compounded semaglutide and tirzepatide — Compounded means mixed to order by a pharmacy, and the FDA has not reviewed it for safety, effectiveness or quality.[17]
- Compounding “essentially a copy” of these drugs has been off the table since the shortages ended in December 2024 (tirzepatide) and February 2025 (semaglutide). The compounding industry challenged that and lost — the Fifth Circuit affirmed for the FDA on August 27, 2026.[16][17][19]
- The price gap that used to justify compounding has mostly closed. ShedRx’s 12-month compounded tirzepatide is $239/month; a brand-name Zepbound single-dose vial from LillyDirect is $299/month. A $60 gap.[2][26]
- Hims and Ro have already stopped — both now list brand-name GLP-1s only. ShedRx has not.[27][28]
- ShedRx’s own state pages for Utah, New York and Texas do not list compounded injections as available — including in Utah, where the company is based.[11][12][13]
- The customer record splits hard: 4.6/5 on Trustpilot across ~1,126 reviews, 1.5/5 on ConsumerAffairs, and 251 BBB complaints in three years. All three are real. We explain why below.[31][32][34]
What the status labels on this page mean
- FDA-approved
- The FDA reviewed the evidence and approved this exact drug product for this use.
- Compounded
- Mixed to order by a pharmacy under a prescription. Not FDA-approved, and not reviewed by the FDA for safety, effectiveness or quality. Not a generic.
- Off-label
- An FDA-approved drug prescribed for something other than what it was approved for. Legal and common, but that use has not been through FDA review.
ShedRx sells prescription weight-loss medication by subscription: you answer a questionnaire, a clinician reviews it, and medication ships monthly. That model is now crowded — Hims, Ro, Noom, Found, Mochi and a dozen smaller operators all sell some version of it. What separates them in September 2026 is no longer price or convenience. It is a single question: are you being sent the FDA-approved drug, or a compounded preparation of it?
ShedRx sells both. Its cheapest and most prominently marketed option is the compounded one. This review is mostly about what that means now, because the answer changed materially in the eighteen months before we wrote it — and most reviews of this category have not caught up.
What ShedRx charges
ShedRx prices by length of commitment, not by dose. The longer you sign up for, the lower the monthly figure. Every price below was read from ShedRx’s own product pages on September 9, 2026.
| Injectable GLP-1 Compounded | 1 mo | 6 mo | 12 mo |
|---|---|---|---|
| Semaglutide | $199 | $179 | $159 |
| Tirzepatide | $299 | $269 | $239 |
Dollars per month, by length of commitment. Both are compounded preparations. The highlighted figures are the ones ShedRx advertises as “starting at” on its homepage — they require a twelve-month commitment.[1][2][3]
| Everything else in the weight-loss range | Per month |
|---|---|
| Foundayo (orforglipron), oral FDA-approved[35] | ≈ $274 |
| Wegovy / Zepbound via “Shed Membership” FDA-approved | Not published |
| Metformin + naltrexone + topiramate Off-label | $169 |
| Naltrexone + bupropion Off-label | $115 |
| MIC + B-12 injection, 2×/week Compounded | $115 |
Foundayo is $149/mo for the medication plus a $125/mo Shed membership. Both tables: ShedRx product pages, read September 9, 2026.[1][2][3][5]
The savings ShedRx advertises check out arithmetically. Twelve months of semaglutide at $159 rather than $199 is exactly the $480 the site claims; six months of tirzepatide at $269 rather than $299 is exactly $180.[1][2] That is more than most subscription services can say, and we note it as a point in ShedRx’s favor.
What ShedRx does not publish is a dose-by-dose price. GLP-1 treatment is titrated upward over months, and at brand-name pharmacies the price often climbs with the dose. ShedRx’s flat monthly figure implies titration is included — but the company never states this in so many words, and the schedule is only visible after you have signed up. We flag it as a gap rather than assuming either way.
A quiet mismatch worth knowing before you click. ShedRx sells a “1 Month” plan on its product pages with no caveat attached. Its Terms and Conditions state that “all programs require a minimum commitment of two (2) full months.”[9] Those two statements cannot both be operative. We could not resolve which one governs at checkout.
The rest of the catalogue
ShedRx also sells NAD+ (nasal spray $144/mo, injection or oral tablet $169/mo), glutathione injection ($119/mo), sermorelin ($199/mo, discounted at the time of reading), low-dose naltrexone ($89/mo), methylene blue ($99/mo), and a hair-loss line starting at $43/mo.[6][7] Health coaching is free at a text-only tier and $49.99/mo for two 20-minute sessions.[8]
Two things about that coaching are worth stating plainly, because ShedRx’s marketing leans on it. The staff named on the homepage hold CHC (certified health coach) and LDN (licensed dietitian-nutritionist) credentials.[3][8] That is real nutrition support and it is more than most competitors bundle. It is not physician follow-up, and the site does not claim it is.
What “compounded” now means
This is the section that matters, so we are going to be precise about dates.
Compounding pharmacies are allowed to make a version of a commercially available drug when that drug is in shortage. Both GLP-1s were, for a long time, and an entire telehealth industry grew inside that window. Then the window closed:
| Date | What happened |
|---|---|
| Dec 19, 2024 | FDA declares the tirzepatide shortage resolved. Compounding grace period: 503A pharmacies to 18 Feb 2025, 503B outsourcing facilities to 19 Mar 2025.[16] |
| Feb 21, 2025 | FDA declares the semaglutide shortage resolved. Grace period: 503A to 22 Apr 2025, 503B to 22 May 2025.[17] |
| May 7, 2025 | A federal district court rules for the FDA against the compounding industry’s trade association.[19] |
| Feb 9, 2026 | Novo Nordisk sues Hims & Hers, alleging its compounded semaglutide used “inauthentic API”.[36] |
| Mar 3, 2026 | FDA announces warning letters to 30 telehealth companies over illegal marketing of compounded GLP-1s.[21] |
| Apr 1, 2026 | FDA clarifies the personalization carve-out: adding B-12 only counts if the amount differs by more than 10% from a commercial combination product and serves a documented, patient-specific need.[17] |
| Apr 30, 2026 | FDA proposes removing semaglutide, tirzepatide and liraglutide from the 503B bulk-substances list entirely. Not finalized as of this writing.[18] |
| Aug 27, 2026 | The Fifth Circuit affirms for the FDA. The compounding industry’s central legal challenge has now failed at every level.[19] |
FDA statements and the Fifth Circuit slip opinion, cited in full below. The highlighted row is the ruling that settled the question.
After a drug leaves the shortage list, a pharmacy may not produce something that is “essentially a copy” of it. The remaining route is personalization for an identified individual patient — a documented clinical reason why the commercially available product will not do. The FDA’s April 1, 2026 clarification states that standard directly.[17] Four weeks later, in a proposed rule that has not been finalized, the agency added that “patient preference and cost savings alone are insufficient justifications” for compounding a copy.[18]
Where does ShedRx sit? Its blog states: “we have partnered with both 503A and 503B pharmacies, allowing us to be flexible and remain compliant as FDA regulations evolve.”[10] That is the whole disclosure. No pharmacy is named anywhere on the site. No specific personalization rationale is described. We are not in a position to say ShedRx is out of compliance — that is a determination for the FDA, and ShedRx was not among the ten companies publicly named in the March 2026 warning-letter wave.[21] What we can say is that the company does not publish what it would take for a reader to check.
What the FDA says about compounded drugs, in its own words: “Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.”[17] ShedRx does carry a version of this line on its individual compounded-product pages. It does not appear in the core Terms and Conditions, and one hub page uses the phrase “FDA approved options” as a page-level heading while listing “Compounded Semaglutide” and “Compounded Tirzepatide” beneath it.[9][15]
The $60 gap
The case for compounded GLP-1s was always economic. Brand-name GLP-1s cost several times the compounded price at list. That was true. It is much less true now, because Novo Nordisk and Eli Lilly both cut their direct-to-consumer cash prices sharply.
Red bars are Compounded; green bars are FDA-approved. Bars scale to the largest figure shown. The grey bars in the scorecard further down mean something different — they are scores, not prices. Sources: ShedRx product pages, LillyDirect price announcement, NovoCare price guide, all read September 9, 2026.[2][25][26]
At the starting dose, ShedRx’s compounded tirzepatide on a twelve-month commitment costs $60 a month less than the FDA-approved drug bought direct from its manufacturer with no commitment at all. On a one-month plan, the two are the same price.
That is the entire trade. Sixty dollars a month, in exchange for a preparation the FDA has not reviewed, from a pharmacy the company will not name, with the legal ground beneath the practice having been narrowed by the FDA and upheld by a federal appeals court less than two weeks before we published this.
Two competitors have already drawn their own conclusion. Hims & Hers resolved Novo Nordisk’s lawsuit in March 2026 by agreeing to sell branded Ozempic and Wegovy and to stop marketing compounded GLP-1s except where medically necessary; its pricing page now lists brand-name products only.[27][36] Ro likewise lists only brand-name GLP-1s.[28] We found no public explanation for Ro’s decision and are not going to invent one.
| Service | Dispenses | Published monthly cost |
|---|---|---|
| ShedRx | Compounded primary, brand resold | Sema $159–199 · Tirze $239–299 |
| Hims & Hers | FDA-approved only | Zepbound $299 · Wegovy pen $199 · plus $149/mo membership |
| Ro Body | FDA-approved only | Zepbound KwikPen $299–449 · plus $74–149/mo membership |
| Noom Med | Compounded primary | $179–299/mo after intro pricing |
| Mochi Health | Compounded primary | Tirze from $90/dose + $79/mo membership |
| Found | Compounded in membership | “as low as $99/month” |
| Calibrate | Dispenses nothing — coaching + insurance navigation | $199/mo, 3-month minimum |
Each company’s own published pricing page, read September 9, 2026.[27][28][29][30] Membership fees at Hims and Ro are charged in addition to medication; ShedRx’s figure is all-in.
Read that table for the one thing it actually shows: ShedRx’s all-in price genuinely beats Hims and Ro once their membership fees are counted, because neither of those figures includes their membership. If the compounded question does not trouble you, ShedRx is priced competitively — though Found and Noom advertise lower entry prices for compounded treatment, and a reader shopping on price alone should check both.
If you want to check ShedRx’s current pricing yourself
Prices in this category move — Lilly cut Zepbound’s vial price by up to $100 in December 2025, and ShedRx runs its own promotions. The figures above are what we read on September 9, 2026. ShedRx’s own weight-loss page is the only place the current numbers are authoritative.
The link below is an affiliate link. If you sign up through it we may earn a commission at no cost to you. Nothing above or below was written to make you click it.
“Microdose GLP-1”
ShedRx sells a “Microdose GLP-1” product — compounded semaglutide from $149/mo, compounded tirzepatide from $199/mo, two-month minimum.[4] Note where it sits in ShedRx’s own navigation: under Longevity and Vitality, not Weight Loss, and marketed for “healthy aging”, “metabolic function” and “mental clarity”.
The term deserves scrutiny because it is doing a lot of work across this whole industry.
“Microdosing is not a medical term. It’s a term that has been popularized on social media.”
— Dr. Amanda Velazquez, Director of Obesity Medicine, Cedars-Sinai[23]
Her colleague Dr. Jeremy Korman is more specific: the amounts sold commercially as a “microdose” — typically around a quarter of a standard dose — are set arbitrarily, with no research basis behind the number.[23] At Tufts Medicine, Dr. Caitlin Polistena puts it as plainly: “we don’t have strong research showing that very low doses are effective for sustained weight loss.”[24]
We looked for a registered randomized controlled trial testing sub-therapeutic GLP-1 dosing for weight loss as a primary endpoint. We did not find one. The registered trials that produced this drug class’s evidence tested it at the doses the FDA went on to approve.
There is a second point, and it is the more consequential one. The FDA’s personalization carve-out requires a documented clinical difference for an identified individual patient. Nothing in that standard treats “a lower dose of the same drug for the same purpose” as a qualifying difference on its own, and no FDA compounding guidance we could find addresses “microdosing” by name.[17][18] A reader should not assume that relabeling a smaller dose as a longevity product changes its regulatory position.
Who evaluates you, and where
The intake is asynchronous. ShedRx describes it as “a 5-minute quiz”, after which “a medical provider will look over your answers and determine if you’re a good fit — no appointment required.”[1][2] There is no live video consultation in the described flow. Coaching sessions, which are a paid add-on, are live.[8]
ShedRx names a physician — Dr. Asad Niazi, MD, MPH — alongside a registered nurse, a licensed dietitian-nutritionist and a certified health coach.[3] That is more than several competitors publish, and more than the men’s-health brand we reviewed alongside this one, which names no clinician at all. The site does not use the title “Medical Director” for anyone.
Then there is the states question, which is where ShedRx’s own published material contradicts its affiliate-facing claim of nationwide GLP-1 availability. ShedRx publishes a resource page for each state listing what is available there. We checked three, including its home state:
What ShedRx’s own state pages list. Swipe sideways for the full third column.
| State | Compounded injections listed? | What is listed instead |
|---|---|---|
| Utah company HQ | No — and neither Wegovy nor Zepbound | GLP-1 drops, lozenges, metformin+naltrexone+topiramate, MIC+B-12, naltrexone+bupropion, Microdose GLP-1 |
| New York | No | The above, plus Wegovy and Zepbound via Shed Membership |
| Texas | No | The above, plus Wegovy and Zepbound via Shed Membership |
ShedRx’s own state resource pages, read September 9, 2026.[11][12][13] We sampled three of fifty states.
In all three — including Utah, where the company is headquartered — the flagship compounded injection is not listed as an available product. We are not going to over-read a three-state sample, and there are innocent explanations: a stale page, a state-by-state formulary that changed faster than the marketing site. But the gap between “GLPs available in all 50 states” and what ShedRx’s own state pages list is real, and a reader in one of those states should confirm before committing to twelve months. ShedRx publishes one page per state at tryshed.com/resources/states/<your-state> — check yours.
What ShedRx publishes about safety
The standard disclaimer — “Compounded medications are not FDA-approved and are prepared by a licensed pharmacy based on a provider’s prescription” — appears on the individual compounded-product pages.[1][2][4] It reads as one line among marketing copy rather than as a distinct warning, but it is there, and that puts ShedRx ahead of several competitors in this category.
The clearest statement ShedRx makes anywhere is buried in an informed-consent document for an oral liposomal GLP-1 early-access program: “I understand that this Oral Liposomal GLP-1 Medication is not FDA approved… safety, efficacy, and quality may differ from those of FDA-approved GLP-1 drugs.”[14] That is exactly the right disclosure. It is also several clicks deep in a specific sign-up flow rather than on the pages that sell the product.
One FDA safety communication is directly relevant to anyone buying compounded GLP-1s in a multi-dose vial, and we did not find it addressed on ShedRx’s marketing pages:
FDA alert, July 26, 2024 — dosing errors with compounded semaglutide. Patients using U-100 insulin syringes drew 5 to 20 times the intended volume from multi-dose compounded vials. Clinicians miscalculating milligram-to-unit conversions dosed patients at 5 to 10 times the intended amount. The FDA recommends compounders supply correctly sized syringes and counsel patients on measurement.[20]
Brand-name pens are pre-measured. Compounded vials are not. This is a real and specific difference between the two routes that price comparisons do not capture.
Separately, on December 5, 2025 the FDA warned about counterfeit Ozempic 1 mg pens (lot PAR1229) found inside the legitimate US supply chain.[22] That is a brand-name counterfeiting problem, not a compounding one — we mention it because it cuts against a simple “brand good, compounded bad” reading, and because a reader buying either route should know how to check a lot number.
The terms you are agreeing to
This is where ShedRx’s contract is least generous, and it is worth reading before the twelve-month tier tempts you.
| Term | What ShedRx’s T&Cs say |
|---|---|
| Minimum | Two full months |
| Cancellation notice | At least 72 hours before the next billing date |
| Refunds | Subscription fees are non-refundable once a patient has been approved for treatment |
| Exceptions | Provider finds you medically ineligible; adverse reaction (refund at 50% of last shipped cycle or pro-rata, whichever is greater); FDA recall or regulatory action |
| Early exit from a long plan | Months already used are repriced retroactively at the higher month-to-month rate. Leaving a 12-month plan early means paying back the discount |
| Unused medication | Non-returnable — federal and state pharmacy law prohibits restocking dispensed prescriptions |
| Renewal | Automatic each billing period |
| Disputes | Binding individual arbitration (AAA), Salt Lake County, Utah, with a class-action waiver |
ShedRx Terms and Conditions, read September 9, 2026.[9] The highlighted row is the clause most likely to cost you money.
The retroactive repricing clause is the one to sit with. The $480 headline saving on a twelve-month semaglutide plan is not a discount you keep — it is a discount you forfeit, retrospectively, if the medication does not agree with you in month four and you stop. Combine that with a refund policy that switches off the moment a provider approves you, and the twelve-month tier is a genuine commitment rather than a payment plan.
What customers report
ShedRx’s public record is unusually contradictory, and we are going to show you both halves rather than average them into something meaningless.
The same company, four scoreboards. Swipe sideways for the detail column.
| Channel | Score | Volume | Detail |
|---|---|---|---|
| Trustpilot (tryshed.com) | 4.6–4.7 / 5 | ~1,126 | 86% five-star, 6% one-star |
| ConsumerAffairs | 1.5 / 5 | 194 | 82% one-star |
| BBB — “Shed”, Lehi UT | 2.85 / 5 Grade B | 155 reviews 251 complaints | Complaints over 3 years. Not BBB-accredited |
| BBB — “ShedRx, LLC”, Gilbert AZ | Not rated | — | BBB “evaluating a pattern of complaints before issuing a rating” |
| — | none found | No threads naming ShedRx on r/Semaglutide, r/tirzepatidecompound or r/WeightLossAdvice |
All read September 9, 2026.[31][32][33][34] BBB’s complaint breakdown: product issues 103, service/repair 72, billing 25, sales/advertising 21, delivery 13, customer service 12, order 5.
Both numbers are real, and the gap is structural rather than mysterious. Trustpilot in this category fills largely from automated post-purchase review requests sent to customers who have just received a shipment and have not yet hit a billing or cancellation problem. ConsumerAffairs and BBB are places people go after something went wrong. Neither is the “true” score. Read them as measuring different moments in the customer relationship.
What is more useful than either number is that the complaints across all three channels describe the same thing. Dated examples: a Trustpilot one-star review on July 29, 2026 describing being charged for a third month that never arrived, with 48-hour chat response times; another on July 13, 2026 alleging billing “without sending meds” after “corporate changes”; on ConsumerAffairs, a reviewer on January 21, 2026 unable to reach anyone to cancel, another on August 6, 2026 billed for medication never received, and a third on January 19, 2026 who waited three weeks past a scheduled injection for the next shipment.[31][34]
Billing continuing while shipments stall is the consistent pattern. It is also exactly the failure mode the 72-hour cancellation notice and non-refundable-after-approval clause make expensive.
What we could not verify
- Which pharmacy compounds ShedRx’s medication. Not named on any page. The disclosure stops at “both 503A and 503B pharmacies”.
- The legal relationship between the two entities. Terms name “Shed Holdings, LLC” (Utah). BBB carries separate profiles for “Shed” (Lehi, UT) and “ShedRx, LLC” (Gilbert, AZ). ConsumerAffairs lists tryshed.com under “ShedRx”. No document we found ties them together explicitly.
- What the promotional link actually discounts. ShedRx’s affiliate landing page carries a promo code in the URL; the portal is blocked by robots.txt and no page describes the code’s terms, scope or duration.
- A dose-by-dose price schedule. Not published. Only visible after signup.
- Full 50-state availability. We sampled three states. The other 47 are unchecked.
- Whether ShedRx was among the 30 companies that received FDA warning letters in early 2026. The FDA did not publish the full roster; ShedRx is not among the ten names we could confirm.
- Whether the “1 Month” plan or the two-month T&C minimum governs at checkout.
- Reddit sentiment. We found no threads. That is not proof none exist.
How we rated ShedRx
We score prescription services against the six criteria on our methodology page. This is a rating of what a service publishes and how well its claims line up with the labeling — not a clinical judgement, not a measure of outcomes, and not a recommendation.
Editorial rating — based on our analysis
2.8 / 5
Six criteria, equally weighted. Read the reasoning, not the number.
States plainly that the products are compounded and not FDA-approved on product pages. Loses ground for a hub page headed “FDA approved options” above compounded listings, and for no FDA disclosure in the core terms.
Names a physician, an RN and a dietitian — better than most. But asynchronous-only intake, and the company’s own state pages do not list the flagship product as available in the three states we checked.
The compounded disclaimer is present. The FDA’s 2024 vial-dosing-error alert — directly relevant to a multi-dose compounded vial — is not addressed on the marketing pages.
Everything is published, which counts. Retroactive repricing on early exit and non-refundable-after-approval are severe, and appear nowhere near the twelve-month price that makes them bite.
“Microdose GLP-1” is sold as a longevity product with no trial evidence for sub-therapeutic dosing, and the term is not recognized in FDA compounding guidance. The advertised savings figures, in contrast, are arithmetically exact.
No pharmacy named, no dose-price schedule, two corporate identities with no stated relationship, and a promotional code whose terms are not published anywhere.
Scores are our reading of published material as of September 9, 2026, applied to the six criteria on our methodology page. They will change if ShedRx publishes more.
Who it suits
Reasonable fit if
- You have already decided you want a compounded GLP-1 and you understand what that means. ShedRx’s twelve-month price is all-in and beats Hims and Ro once their membership fees are counted — though Found and Noom advertise lower entry prices.
- You want nutrition coaching bundled rather than sold separately — the free text tier is genuinely included, and the staff hold real credentials.
- You want one provider for a GLP-1 and adjunct prescriptions (metformin combinations, naltrexone-bupropion) rather than two.
- You are confident you will stay on treatment for the full term you sign up for.
Look elsewhere if
- You want the FDA-approved drug. Buy Zepbound direct from LillyDirect at $299 for the starting dose — $60 more than ShedRx’s twelve-month compounded tier, with no commitment and a pre-measured pen or vial.
- You are unsure whether you will tolerate a GLP-1. The retroactive repricing clause makes stopping early expensive, and refunds close once a provider approves you.
- You need to know which pharmacy makes your medication. ShedRx does not say.
- You want live clinician contact rather than a questionnaire.
- You live in a state where ShedRx’s own resource page does not list compounded injections — check yours first.
The comparison worth doing before you sign up
Two live prices, sixty dollars apart: $239 and $299 a month. One is a compounded preparation on a twelve-month lock-in. The other is an FDA-approved drug from its manufacturer with no commitment at all. Open both and decide with the numbers in front of you.
The first link is an affiliate link — we may earn a commission at no cost to you. The second is not, and we earn nothing from it.
Frequently asked questions
Is compounded semaglutide the same as Wegovy or Ozempic?
No. A compounded preparation is mixed to order by a pharmacy and is not FDA-approved. In the FDA’s own words, it does not “review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.”[17] It is also not a generic — generics go through an FDA approval pathway that proves equivalence to the brand. Compounded versions do not.
Is it still legal for ShedRx to sell compounded semaglutide and tirzepatide in 2026?
Compounding something that is “essentially a copy” of an approved drug is not permitted once the drug is off the shortage list, which both have been since 2025. The remaining route is a documented, patient-specific clinical reason. In an April 2026 proposed rule — not yet finalized — the FDA added that “patient preference and cost savings alone are insufficient justifications” for compounding a copy.[18] Whether any particular company’s practice qualifies is a determination for the FDA, not for us. What we can say is that ShedRx does not publish the information a reader would need to assess it, and that the compounding industry’s legal challenge to the FDA’s position was rejected by the Fifth Circuit on August 27, 2026.[19]
How much cheaper is ShedRx than brand-name Zepbound?
At the starting dose, $60 a month — ShedRx’s twelve-month compounded tirzepatide at $239 against a Zepbound 2.5 mg single-dose vial at $299 from LillyDirect.[2][26] On ShedRx’s one-month plan the two are the same price. The gap widens at higher doses, because Zepbound’s vial price rises to $399 and then $449 while ShedRx’s monthly figure does not visibly change — though ShedRx does not publish a dose-price schedule, so we cannot confirm that holds.
What is “microdosing” a GLP-1, and does it work?
It refers to taking a fraction of the approved dose. There is no clinical-trial evidence that sub-therapeutic dosing produces meaningful or durable weight loss, and obesity-medicine specialists at Cedars-Sinai describe the commercial amounts as set “arbitrarily” with no research basis.[23] Dr. Amanda Velazquez of Cedars-Sinai states directly that “microdosing is not a medical term.”[23] No FDA compounding guidance we could find addresses it by name.
Can I cancel ShedRx, and what does it cost?
You must give at least 72 hours’ notice before the next billing date. Subscription fees are non-refundable once a provider has approved you for treatment, and if you leave a multi-month plan early, the months you already used are repriced retroactively at the higher month-to-month rate — so you repay the discount.[9] Dispensed medication cannot be returned, because pharmacy law prohibits restocking it.
Why does ShedRx have a 4.6 on Trustpilot and a 1.5 on ConsumerAffairs?
Because the two platforms sample different moments. Trustpilot in this category fills largely from automated requests sent shortly after a shipment arrives. ConsumerAffairs and BBB are where people go after a problem — and BBB has logged 251 complaints over three years, with its Arizona profile marked “not rated” while it evaluates “a pattern of complaints.”[31][32][33][34] The complaints are consistent with each other: billing continuing while shipments stall.
Does ShedRx ship to every state?
The affiliate-facing claim is that GLP-1s are available in all 50 states. ShedRx’s own state resource pages tell a narrower story: in Utah, New York and Texas — the three we checked — compounded semaglutide and tirzepatide injections are not listed among the available products, though drops, lozenges, microdose and brand-name options are.[11][12][13] ShedRx publishes one page per state at tryshed.com/resources/states/<your-state>; check yours before committing.
Bottom line
ShedRx is priced competitively and publishes more than several of its rivals — a named physician, exact savings arithmetic, a compounded disclaimer on its product pages, and terms that, however unfriendly, are actually written down.
But it is selling the cheaper side of a trade that has been getting worse for eighteen months. The FDA closed the shortage window, narrowed the personalization carve-out, warned thirty telehealth companies about how they market compounded GLP-1s, and proposed removing these molecules from the 503B bulk list entirely. A federal appeals court upheld the FDA’s position less than two weeks before we published this. Meanwhile Lilly and Novo cut their cash prices, and the two largest telehealth competitors stopped selling compounded GLP-1s altogether.
What is left of the original argument is $60 a month at the starting dose, in exchange for a preparation the FDA has not reviewed, from a pharmacy that is not named, on a twelve-month commitment that reprices retroactively if you leave. For some readers that trade still makes sense. It is a narrower trade than it was, and it should be made with the numbers visible rather than the marketing.
Read next
- Compounded vs brand-name GLP-1: what the difference actually is — the background to everything on this page.
- Semaglutide vs tirzepatide — which molecule, and why the price differs.
- GLP-1 side effects — what the approved labeling says.
- Who qualifies for GLP-1 treatment — the eligibility criteria a questionnaire is screening for.
- All our weight-loss coverage
Sources
- ShedRx — Compounded Semaglutide Injections product page. tryshed.com. Read Sep 9, 2026.
- ShedRx — Compounded Tirzepatide Injections product page. tryshed.com. Read Sep 9, 2026.
- ShedRx — homepage and pricing page. tryshed.com/pricing. Read Sep 9, 2026.
- ShedRx — Microdose GLP-1. tryshed.com/products/microdose. Read Sep 9, 2026.
- ShedRx — Foundayo (orforglipron). tryshed.com/products/foundayo. Read Sep 9, 2026.
- ShedRx — Longevity and NAD+ product pages. tryshed.com/products/longevity. Read Sep 9, 2026.
- ShedRx — Men’s and Women’s Hair Solutions. tryshed.com. Read Sep 9, 2026.
- ShedRx — Health Coaching. tryshed.com/products/health-coaching. Read Sep 9, 2026.
- ShedRx — Terms and Conditions. tryshed.com/resources/legal/terms. Read Sep 9, 2026.
- ShedRx blog — “What are the types of compounded pharmacies and how do FDA rulings affect them”. tryshed.com. Read Sep 9, 2026.
- ShedRx — Utah state resource page. tryshed.com/resources/states/utah. Read Sep 9, 2026.
- ShedRx — New York state resource page. tryshed.com. Read Sep 9, 2026.
- ShedRx — Texas state resource page. tryshed.com. Read Sep 9, 2026.
- ShedRx — Informed consent, oral liposomal GLP-1 formulation. tryshed.com. Read Sep 9, 2026.
- ShedRx — GLP-1 Injections hub page. tryshed.com. Read Sep 9, 2026.
- FDA — Declaratory order, tirzepatide injection shortage resolved, December 19, 2024. fda.gov.
- FDA — “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize” (semaglutide shortage resolved February 21, 2025; updated April 1, 2026), and FDA, “Human Drug Compounding Laws”. fda.gov.
- FDA proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, April 30, 2026 (comment period closed June 29, 2026; not finalized at the time of writing), as summarised by Orrick. orrick.com.
- Outsourcing Facilities Association v. FDA — N.D. Tex. ruling for FDA May 7, 2025; US Court of Appeals for the Fifth Circuit, No. 25-10758, affirmed August 27, 2026. ca5.uscourts.gov (slip opinion).
- FDA — “FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products”, July 26, 2024. fda.gov.
- FDA — “FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s”, March 3, 2026. fda.gov.
- FDA — “FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in US drug supply chain”, December 5, 2025. fda.gov.
- Cedars-Sinai — “Can microdosing GLP-1s promote health and weight loss?” Comments from Dr. Amanda Velazquez and Dr. Jeremy Korman. cedars-sinai.org.
- Tufts Medicine — “Microdosing GLP-1s: your questions answered”. Comments from Dr. Caitlin Polistena. tuftsmedicine.org.
- NovoCare — Wegovy self-pay price guide. novocare.com. Read Sep 9, 2026.
- Eli Lilly — “Lilly lowers price of Zepbound (tirzepatide) single-dose vials”, effective December 1, 2025. investor.lilly.com.
- Hims & Hers — weight loss drug pricing page. hims.com. Read Sep 9, 2026.
- Ro — weight loss pricing page. ro.co. Read Sep 9, 2026.
- Noom Med pricing and Found program pricing. noom.com · joinfound.com. Read Sep 9, 2026.
- Mochi Health medications page and Calibrate pricing page. joinmochi.com · joincalibrate.com. Read Sep 9, 2026.
- Trustpilot — tryshed.com review page. trustpilot.com. Read Sep 9, 2026.
- Better Business Bureau — “Shed”, Lehi, Utah. bbb.org. Read Sep 9, 2026.
- Better Business Bureau — “ShedRx, LLC”, Gilbert, Arizona. bbb.org. Read Sep 9, 2026.
- ConsumerAffairs — ShedRx. consumeraffairs.com. Read Sep 9, 2026.
- Eli Lilly — “FDA approves Lilly’s Foundayo (orforglipron)”, April 1, 2026. investor.lilly.com.
- Novo Nordisk — company statement on litigation against Hims & Hers, February 9, 2026; resolution announced March 9, 2026. novomedlink.com.
This article is an evidence synthesis, not physician-reviewed content. It is not medical advice and does not establish a patient relationship. GLP-1 receptor agonists are prescription medications with serious potential side effects and contraindications, including a boxed warning for thyroid C-cell tumors on the approved products; consult the FDA-approved prescribing information and a US-licensed clinician before starting, changing or stopping any treatment. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. We do not publish results claims, before-and-after images or weight-loss figures for any service we review. BalanzGM has an affiliate relationship with ShedRx and may earn a commission from qualifying sign-ups made through links on this page; we have no affiliate relationship with Eli Lilly, Novo Nordisk, Hims & Hers, Ro, Noom, Found, Mochi or Calibrate, all of which are named above.
Related review
bmiMD review — the same business model at $99 a month instead of $249 — and an F from the Better Business Bureau.
